Pretax income is the income that a company earns before paying income taxes. Cingulate's pretax income for the
three
months ended in Dec. 2024 was $-6.13 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-15.55 Mil.
Cingulate's pretax margin was %.
Cingulate Pre-Tax Income Historical Data
The historical data trend for Cingulate's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cingulate's Pre-Tax Income
For the Biotechnology subindustry, Cingulate's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cingulate's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cingulate's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Cingulate's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cingulate (NAS:CING) Pre-Tax Income Explanation
Cingulate's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cingulate Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Cingulate's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CING has been successfully added to your 